/
QDEL
$18.23+$4.44 (+32.20%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$940.4M
68M shares
52-week range
$9.92 – $35.58
32% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-110.37
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $522.3M | $534.9M | $1.66B | $1.70B | $3.27B | $3.00B | $2.78B | $2.73B |
| Cost of revenue | $206.6M | $214.1M | $312.8M | $420.3M | $1.33B | $1.50B | $1.50B | $1.46B |
| Gross profit | $315.7M | $320.8M | $1.35B | $1.28B | $1.94B | $1.50B | $1.29B | $1.27B |
| Gross margin | 60.4% | 60.0% | 81.2% | 75.3% | 59.3% | 49.9% | 46.2% | 46.7% |
| R&D | $51.6M | $52.6M | $84.3M | $95.7M | $187.9M | $246.8M | $218.7M | $186.2M |
| Operating income | $95.9M | $92.7M | $1.06B | $906.0M | $843.7M | $139.1M | −$1.96B | −$919.2M |
| EBITDA | $133.9M | $139.8M | $1.10B | $953.3M | $1.09B | $607.0M | −$1.49B | −$488.1M |
| Net income | $74.2M | $72.9M | $810.3M | $704.2M | $548.7M | −$10.1M | −$2.05B | −$1.13B |
| Net margin | 14.2% | 13.6% | 48.8% | 41.5% | 16.8% | -0.3% | -73.7% | -41.5% |
| EPS (diluted) | 1.74 | 1.73 | 18.60 | 16.43 | 9.56 | -0.15 | -30.54 | -16.69 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.7B | $1.84 | $1.67–$1.99 | 2 |
| 2027 | $2.8B | $2.49 | $2.32–$2.65 | 3 |
| 2028 | $2.9B | $2.99 | $2.94–$3.04 | 1 |
| 2029 | $3.0B | $3.11 | $3.05–$3.16 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
QuidelOrtho Corporation Common Stock
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
www.quidelortho.com- Employees
- 6,500
- IPO / List date
- Aug 4, 1981
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds QDEL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-06-30 | 104,412 | $3.5M |
| Bridgewater Associatesas of 2024-12-31 | 6,257 | $278.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded QDEL yet.
